Please login to the form below

Not currently logged in

Shire acts against Sandoz and Amneal

Shire is taking legal action against Amneal and Sandoz for patent infringements

Shire has filed lawsuits in the US District Court for the District of New Jersey against each of Amneal Pharmaceuticals and Sandoz for infringement of Shire's VYVANSE patents.

The lawsuits were initiated in response to abbreviated new drug applications filed by Amneal and Sandoz seeking US Food and Drug Administration (FDA) approval to market and sell generic versions of all currently approved doses of VYVANSE.

Under the Hatch-Waxman Act, the FDA must refrain from approving the Sandoz and Amneal ANDAs for 30 months (expiring August 23, 2014), or until a district court decision finding that the patents are invalid or not infringed, whichever occurs earlier.

Sandoz declined to comment, while Amneal was unavailable to comment at the time of writing.

4th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked